XL-protein announces publication of key scientific data on its PASylation® technology
FREISING, GERMANY, August 30, 2013 – XL-protein GmbH announced…
XL-protein and GENERIUM sign broad therapeutic license and collaboration agreement to develop PASylated therapeutics for the Russian Federation
Freising, Germany & Moscow, Russia, June 25, 2013
XL-protein…
XL-protein and Wacker Biotech produce a PASylated antibody fragment (Fab) with prolonged plasma half-life at more than four grams per liter culture in an E. coli expression system
High Yield with ESETEC® and PASylation®: Wacker Biotech and…